Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 04, 2023

Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-Escalated Chemotherapy for HR+/ERBB2+

JAMA Oncology


Additional Info

JAMA Oncology
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial
JAMA Oncol 2023 May 11;[EPub Ahead of Print], O Gluz, UA Nitz, M Christgen, S Kuemmel, J Holtschmidt, J Schumacher, A Hartkopf, J Potenberg, K Lüedtke-Heckenkamp, M Just, C Schem, R von Schumann, C Kolberg-Liedtke, CZ Eulenburg, T Schinköthe, M Graeser, R Wuerstlein, RE Kates, HH Kreipe, N Harbeck

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading